US equities
|
NVDA
$240.15
▲+0.52%
SPCX
$172.06
▲+0.57%
MU
$1,059.01
▼-0.47%
MRVL
$286.45
▲+5.60%
AMD
$654.31
▲+3.57%
INTC
$114.28
▼-1.65%
AVGO
$378.48
▲+4.41%
TSLA
$379.54
▲+0.21%
NVDA
$240.15
▲+0.52%
SPCX
$172.06
▲+0.57%
MU
$1,059.01
▼-0.47%
MRVL
$286.45
▲+5.60%
AMD
$654.31
▲+3.57%
INTC
$114.28
▼-1.65%
AVGO
$378.48
▲+4.41%
TSLA
$379.54
▲+0.21%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Lexaria Bioscience Corp. - Common Stock
(NQ:
LEXX
)
2.995
+0.225 (+8.12%)
Delayed Quote
Updated: 2:43 PM EDT, Oct 6, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexaria Bioscience Corp. - Common Stock
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
Lexaria Announces 2021 Annual Meeting Results
June 29, 2021
KELOWNA, BC / ACCESSWIRE / June 29, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
June 17, 2021
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Lexaria Hits Important Anti-Viral Milestone with In Vitro Test of DehydraTECH(TM)
June 17, 2021
New York, New York--(Newsfile Corp. - June 17, 2021) - PCG Digital -- Lexaria Bioscience Corp. (NASDAQ: LEXX) hit a...
Via
Newsfile
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
June 15, 2021
Gainers Clearside Biomedical (NASDAQ:CLSD) stock increased by 50.99% to $4.56 during Tuesday's pre-market session. The market value of their outstanding shares is at $...
Via
Benzinga
Lexaria Drug Delivery Platform Enables up to Three-Fold Increase in Oral Delivery of Antiviral Drugs
June 15, 2021
DehydraTECH™ improves delivery into bloodstream of orally administered remdesivir and ebastine in study VIRAL-A20-2 KELOWNA, BC / ACCESSWIRE / June 15, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Lexaria Provides Progress Report on Six R&D Programs
June 09, 2021
- All studies are using DehydraTECH™ 2.0 formulations for multiple market applications, including antivirals, hypertension, NSAIDs and oral nicotine - These studies are part of Lexaria's 2021 applied...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Animal Testing
Intellectual Property
Lexaria Issues Progress Report on First Human Clinical Study of 2021, HYPER-H21-1
June 07, 2021
- Dosing Is Complete in First of Three Human Clinical Studies Hoped To Validate Lexaria’s Patented Technology for Hypertension Relief - Study Tested an Advanced “DehydraTECH™ 2.0” CBD Formulation -...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Lexaria Bioscience on Drug Delivery Technology and its Patented DehydraTECH
↗
June 03, 2021
Lexaria Bioscience Corp. (NASDAQ: LEXX) Chairman and CEO Chris Bunka began the Benzinga Global Small Cap Business Conference presentation on May 13, 2021, by clarifying a few key...
Via
Benzinga
Lexaria's DehydraTECH(TM)-Enabled Remdesivir and Ebastine Effectively Inhibit the COVID-19 SARS-CoV-2 Virus
June 03, 2021
KELOWNA, BC / ACCESSWIRE / June 3, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Lexaria's DehydraTECHTM Drug Delivery Technology Is Investigating Applications in Multiple Markets Valued Over USD $100 Billion
↗
June 02, 2021
Developing a safe and effective drug is important, but it’s only part of the picture. For the therapeutic effect of a drug to be effective, it largely depends on the...
Via
Benzinga
VIDEO: Benzinga Cannabis Hour | Nasdaq Edition Ft. The Alkaline Water Company And Lexaria Bioscience
↗
May 27, 2021
Benzinga Cannabis Hour is a weekly show that focuses on the latest news and business trends in the cannabis industry. So, let...
Via
Benzinga
Topics
Cannabis
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
May 20, 2021
Gainers VistaGen Therapeutics (NASDAQ:VTGN) shares moved upwards by 14.34% to $2.63 during Thursday's pre-market session. The market value of their outstanding shares...
Via
Benzinga
Lexaria's Newest DehydraTECH(TM) 2.0 Formulation Tested in Study HYPER-A21-2 Demonstrates Its Strongest CBD Absorption Results Ever
May 20, 2021
- New formulation delivers up to 2,708% more CBD into bloodstream* - Human clinical hypertension study HYPER-H21-1 also progressing KELOWNA, BC / ACCESSWIRE / May 20, 2021 / Lexaria Bioscience Corp....
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Animal Testing
Intellectual Property
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
↗
May 12, 2021
Gainers Second Sight Medical (NASDAQ:EYES) shares increased by 25.39% to $6.27 during Wednesday's pre-market session. The company's market cap stands at $174.9...
Via
Benzinga
Lexaria Strengthens Its International Patent Portfolio to 19 Patents Granted
May 12, 2021
- New patent granted in India bolsters worldwide patent coverage, adding to existing patents in the EU, the U.S., and Australia KELOWNA, BC / ACCESSWIRE / May 12, 2021 / Lexaria Bioscience Corp....
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
Lexaria Bioscience Corp. Discusses Potential of DehydraTECH(TM) CBD for Revolutionary Hypertension Solution with The Stock Day Podcast
May 07, 2021
Phoenix, Arizona--(Newsfile Corp. - May 7, 2021) - The Stock Day Podcast welcomed Lexaria Bioscience Corp. (NASDAQ: LEXX) ("the Company"),...
Via
Newsfile
Topics
Intellectual Property
Lexaria to Present at the Benzinga Global Small Cap Conference on May 13, 2021 at 3:50 p.m. ET
May 07, 2021
Lexaria Recently Announced Favorable Data on Its First Animal Study, As Well as the Commencement of Its First Human Clinical Study, Under Its 2021 Hypertension R&D Program KELOWNA, BC / ACCESSWIRE /...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
32 Stocks Moving in Friday's Pre-Market Session
↗
May 07, 2021
Gainers Assertio Holdings, Inc. (NASDAQ: ASRT) shares rose 44.2% to $0.7190 in pre-market trading after the company reported better-than-expected Q1 results. iBio, Inc. (NYSE:...
Via
Benzinga
72 Biggest Movers From Yesterday
↗
May 07, 2021
Gainers SemiLEDs Corporation (NASDAQ: LEDS) shares surged 85.8% to settle at $10.22 on above-average volume. Liquidity Services, Inc. (NASDAQ: LQDT) jumped 37.7% to settle at $25...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
May 06, 2021
Gainers Lexaria Bioscience (NASDAQ:LEXX) shares rose 53.87% to $7.74 during Thursday's regular session. As of 12:30 EST, Lexaria Bioscience's stock is trading at a...
Via
Benzinga
58 Stocks Moving In Thursday's Mid-Day Session
↗
May 06, 2021
Gainers Stealth BioTherapeutics Corp (NASDAQ: MITO) shares surged 92.9% to $2.3150. Stealth BioTherapeutics presented at the Association for Research in Vision and Ophthalmology...
Via
Benzinga
Mid-Morning Market Update: Markets Mostly Lower; Kellogg Earnings Beat Views
↗
May 06, 2021
Following the market opening Thursday, the Dow traded down 0.03% to 34,218.62 while the NASDAQ fell 0.70% to 13,487.34. The S&P also fell, dropping 0.31% to 4,154.86. The U.S...
Via
Benzinga
Topics
Earnings
Stocks
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
May 06, 2021
Gainers Stealth BioTherapeutics (NASDAQ:MITO) stock moved upwards by 58.33% to $1.9 during Thursday's pre-market session. The market value of their outstanding shares...
Via
Benzinga
Lexaria Issues Successful Results from First 2021 Study, HYPER-A21-1
May 06, 2021
- Up to 2,178% more CBD delivered into bloodstream* - Up to 1,737% more CBD delivered into brain tissue* KELOWNA, BC / ACCESSWIRE / May 6, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW)...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
BTV Explores Investment Options in Life Sciences
May 06, 2021
Vancouver, British Columbia--(Newsfile Corp. - May 6, 2021) - On national TV Sat. May 8 & Sun. May 9, 2021...
Via
Newsfile
Lexaria Bioscience Corp., Proprietary Drug Delivery Technology, CEO Clip Video
April 27, 2021
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2021) - Lexaria Bioscience Corp. (CSE: LXX) (NASDAQ: LEXX) - Chris Bunka,...
Via
Newsfile
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
↗
April 22, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,...
Via
Benzinga
Lexaria Commences Human Clinical Hypertension Study
April 22, 2021
- Study to examine DehydraTECHTM CBD's ability to control blood pressure - First of three human clinical studies hoped to validate Lexaria's patented technology for hypertension relief KELOWNA, BC /...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
The Daily Biotech Pulse: Precision Biosciences Regains Rights To CAR T Candidates, CFO Changes, 2 IPOs
↗
April 16, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Ardelyx, Inc. (NASDAQ:...
Via
Benzinga
Lexaria Appoints New Chief Financial Officer and Issues Consultant Warrants
April 15, 2021
KELOWNA, BC / ACCESSWIRE / April 15, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces the...
From
Lexaria Bioscience Corp.
Via
AccessWire
Topics
Intellectual Property
< Previous
1
2
...
26
27
28
29
30
31
32
33
Next >
